insulin NPH — Competitive Intelligence Brief

insulin NPH (insulin NPH) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intermediate-acting insulin. Area: Diabetes.

marketed Intermediate-acting insulin Insulin receptor Diabetes Small molecule

Target snapshot

insulin NPH (insulin NPH) — Novo Nordisk A/S. Insulin NPH is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
insulin NPH TARGET	insulin NPH	Novo Nordisk A/S	marketed	Intermediate-acting insulin	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intermediate-acting insulin class)

1. Novo Nordisk A/S · 2 drugs in this class
2. Sanofi · 2 drugs in this class
3. Geropharm · 1 drug in this class
4. Providence Health & Services · 1 drug in this class
5. Taipei Veterans General Hospital, Taiwan · 1 drug in this class
6. Charles Drew University of Medicine and Science · 1 drug in this class
7. Wockhardt · 1 drug in this class
8. Eli Lilly and Company · 1 drug in this class